Home > Insider Trading > Filing (0001209191-14-027895)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1131324	Genomic Health Inc	GHDX	Services-Medical Laboratories (8071)	770552594

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1337334	Steven Shak	301 Penobscot Drive Redwood City CA 94063	Evp Of R&D	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-04-14	6,959	$2.88	318,547	No	4	M	Direct
Common Stock	Disposition	2014-04-14	6,959	$26.24	311,588	No	4	S	Direct
Common Stock	Acquisiton	2014-04-14	41	$2.88	311,629	No	4	M	Direct
Common Stock	Disposition	2014-04-14	41	$26.80	311,588	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2014-04-14	6,959	$0.00	6,959	$2.88
Common Stock	Employee Stock Option (right to buy)	Disposition	2014-04-14	41	$0.00	41	$2.88

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
27,389		2014-12-02	No	4	M	Direct
27,348		2014-12-02	No	4	M	Direct

Footnotes

This sale of common stock was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on September 9, 2013.
Represents weighted average sale price. Actual sale prices ranged from $25.76 to $26.67.
Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
Includes an aggregate of 10,594 shares of common stock issuable pursuant to previously reported restricted stock unit awards that have not vested.
Represents actual sale price.
The option became exercisable as to 25% of the shares on December 2, 2005, and becomes exercisable as to 1/48th of the shares each full month thereafter.